Hawaii Isotope Tech Opens $20M Cancer Imaging Facility
Hawaii Isotope Technology (HIT) officially opened its new, $20 million facility dedicated to cancer imaging drug production on Monday. The facility, located in [Location - *This would need to be added from an external source if available, as it's not in the original*], significantly expands the company’s capabilities in providing essential medical isotopes for diagnostic imaging.
The construction of the state-of-the-art facility spanned 28 months and represents a substantial investment in Hawaii’s growing biotechnology sector. A key component of the facility is an 80,000-pound cyclotron, a particle accelerator crucial for producing radioactive isotopes. This cyclotron was specially imported from Sweden, highlighting the advanced technology incorporated into the operation.
These isotopes are vital for Positron Emission Tomography (PET) scans, a non-invasive imaging technique widely used to diagnose and monitor various cancers. PET scans allow doctors to visualize metabolic activity within the body, aiding in early detection and treatment planning. HIT’s facility will focus on producing Fluorine-18 (F-18), a key isotope used in the most common PET imaging drug, Fluorodeoxyglucose (FDG).
HIT anticipates commencing production of FDG by the end of the current year. This increased domestic production capacity is expected to reduce reliance on overseas suppliers and improve access to these critical imaging agents for hospitals and clinics across the region and potentially beyond. The company’s expansion underscores its commitment to advancing medical technology and improving patient care through innovative isotope solutions.
